BS_N5B2CZMH
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 36.10381077529566
- age_years
- 12.852
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.649
- INTERFERON_GAMMA_RESPONSE+0.531
- COAGULATION+0.506
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.491
- APICAL_SURFACE+0.470
- ALLOGRAFT_REJECTION+0.395
- INFLAMMATORY_RESPONSE+0.380
- MYOGENESIS+0.346
- IL6_JAK_STAT3_SIGNALING+0.333
- TNFA_SIGNALING_VIA_NFKB+0.323
Top 10 suppressed
- MYC_TARGETS_V2-0.641
- MYC_TARGETS_V1-0.616
- OXIDATIVE_PHOSPHORYLATION-0.590
- E2F_TARGETS-0.562
- G2M_CHECKPOINT-0.488
- DNA_REPAIR-0.437
- PROTEIN_SECRETION-0.382
- MTORC1_SIGNALING-0.375
- UNFOLDED_PROTEIN_RESPONSE-0.342
- MITOTIC_SPINDLE-0.269
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclcA055A_S52.txt | — | cohortMD2 | 0.939 |
| 2 | BS_E2Z940S4 | Meningioma | — | 0.936 |
| 3 | SRR2771286 | — | — | 0.927 |
| 4 | BS_2SHWPB5P | ganglioneuroblastoma | — | 0.926 |
| 5 | MDT-AP-1152 | Med | Medulloblastoma | 0.923 |
| 6 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.922 |
| 7 | TCGA-60-2715-01A-01R-0851-07 | — | cohortSQ1 | 0.920 |
| 8 | TCGA-D8-A73U-01A-11R-A33J-07 | — | D | 0.917 |
| 9 | MNG809 | — | — | 0.915 |
| 10 | sclc55A_S50.txt | — | cohortMD2 | 0.914 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.649 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.531 | Idelalisib | — uncovered |
| COAGULATION | 0.506 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.491 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.470 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.395 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYOGENESIS | 0.346 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.333 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.323 | Inavolisib | — uncovered |
| COMPLEMENT | 0.286 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.276 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.233 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.221 | Inavolisib | — uncovered |
| APOPTOSIS | 0.219 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.214 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.193 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.188 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.174 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |